PipelineReview.com1h
Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
SHANGHAI, China and NORTH CHICAGO, IL, USA I January 13, 2025 I Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc.
PipelineReview.com1h
AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program
NORTH CHICAGO, IL and ROCKVILLE, MD, USA I January 13, 2025 I AbbVie (NYSE: ABBV) and REGENXBIO Inc. (Nasdaq: RGNX) today announced updates to the ...
PipelineReview.com1h
Lilly to acquire Scorpion Therapeutics’ mutant-selective PI3Kα inhibitor program
The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Kα inhibitor ...
PipelineReview.com9h
Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel
TEL AVIV, Israel I January 13, 2025 I Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) ...
PipelineReview.com9h
Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs
NEW HAVEN, CT, USA and UTRECHT, The Netherlands and CAMBRIDGE, MA, US AI January 12, 2025 I Biohaven Ltd. (NYSE: BHVN) and Merus N.V. (Nasdaq:MRUS), ...
PipelineReview.com9h
GSK Enters Agreement to Acquire IDRx, Inc.
PLYMOUTH, MA, USA I January 13, 2025 I GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK ...
PipelineReview.com9h
Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
MELBOURNE, Australia and INDIANAPOLIS, IN, USA I January 12, 2025 I Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today ...
PipelineReview.com2d
Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
NEW YORK, NY. USA I January 10, 2025 I Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating ...
PipelineReview.com2d
NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers
BELTSVILLE, MD, USA I January 10, 2025 I NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing ...
PipelineReview.com2d
Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States
INCHEON, Korea and TEL AVIV, Israel I January 10, 2025 I Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) announced ...
PipelineReview.com2d
Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)
TYRA appoints urologic oncologist, Erik Goluboff, M.D., as SVP, Clinical Development to lead NMIBC--First patient expected to be dosed in SURF302 in Q2 2025-CARLSBAD, CA, USA I J ...
PipelineReview.com2d
Ouro Medicines Launches to Define the Future of Treatment for People with Immune-Mediated Diseases
Ouro will leverage $120 million in funding to develop novel T cell engagers with potential to reset the immune system in patients with chronic immune-mediated ...